Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics, Inc. Common Stock

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.  Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.  Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. 

For more information, please visit www.lexeotx.com.

Sarepta Therapeutics

Woodline Partners

Alexandria Venture Investments

Omega Funds

PBM Capital Group

Invus

Alzheimer's Drug Discovery Foundation

Janus Henderson Investors

Longitude Capital

Lundbeckfonden Ventures

CAM Capital

Verition Fund Management

D1 Capital Partners

Eventide

Gray’s Creek Capital Partners

Intus Capital

Laurion Capital Management

Lexeo Therapeutics

Happy holidays to the team members, friends, family, partners, physicians and patients who have contributed to Lexeo’s work in 2023!

In 2023, Lexeo participated in numerous local events to join forces with patient advocates who are raising awareness about devastating diseases such as #Alzheimer’s, #FriedreichsAtaxia and #ArrhythmogenicCardiomyopathy.
 
Look back on some of our favorite photos from the year with Friedreich's Ataxia Research Alliance (FARA) and Alzheimer's Association®!

We are pleased to announce the FDA has granted Orphan Drug designation and Fast Track designation to LX2020, our #genetherapy candidate designed to treat arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).

Read the full press release here: https://lnkd.in/eq6wzhin

$LXEO shares began trading on Nasdaq last month.
 
Here's a peek behind the curtain of the biggest highlights from IPO day, ringing the Nasdaq closing bell and our event celebrating the Lexeo team for making this possible!
 
#LexeoListed

Yesterday, we reported our Q3 financial results and operational highlights. Check out the highlights below or read the full press release here: https://bit.ly/3Njy60f

	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue	85.55K -	37K 56.75%
cost of revenue	6.70K -									496K -
gross profit	78.85K -	37K 53.07%								-496K -
selling and marketing expenses
general and administrative expenses		3.08M -		3.81M -	2.85M 25.14%	2.74M 3.96%	3.03M 10.51%	6.76M 123.46%	7.55M 11.61%		8.12M -
selling general and administrative expenses	2.45M -	3.08M 25.67%		3.81M -	2.85M 25.14%	2.74M 3.96%	3.03M 10.51%	6.76M 123.46%	7.55M 11.61%	6.49M 13.98%	8.12M 25.04%
research and development expenses	10.15M -	12.27M 20.90%		11.39M -	16.44M 44.36%	11.24M 31.65%	17.25M 53.49%	8.21M 52.39%	15.74M 91.74%	16.56M 5.20%	23.42M 41.44%
other expenses					-4K -	-3K 25%	1K 133.33%	-7K 800%	-5K 28.57%
cost and expenses	12.60M -	15.35M 21.76%		15.20M -	19.29M 26.93%	13.97M 27.55%	20.27M 45.07%	14.97M 26.14%	23.29M 55.54%	23.55M 1.11%
operating expenses	12.60M -	15.35M 21.83%		15.20M -	19.29M 26.93%	13.97M 27.55%	20.27M 45.07%	14.97M 26.14%	23.29M 55.54%	23.05M 1.02%	31.54M 36.82%
interest expense		9K -		54K -	50K 7.41%	53K 6%	52K 1.89%	50K 3.85%	37K 26%	35K 5.41%	-35K 200%
ebitda	-12.51M -	-15.13M 20.95%		-14.08M -	-18.16M 29.00%	-13.39M 26.28%	-19.32M 44.34%	-13.39M 30.71%	-21.17M 58.11%	-23.05M 8.90%
operating income	-12.52M -	-15.31M 22.30%		-15.20M -	-19.29M 26.93%	-13.97M 27.55%	-20.27M 45.07%	-14.97M 26.14%	-23.29M 55.54%	-23.55M 1.11%
depreciation and amortization	6.70K -	177K 2,541.00%		445K -	447K 0.45%	587K 31.32%	460K 21.64%	490K 6.52%	476K 2.86%	496K 4.20%
total other income expenses net	17.43K -	168K 863.86%		620K -	-4K 100.65%	-3K 25%	-271K 8,933.33%	-265K 2.21%	-5K 98.11%	2.31M 46,340%
income before tax	-12.50M -	-15.14M 21.13%		-14.58M -	-18.66M 27.99%	-13.44M 27.96%	-20.11M 49.60%	-14.19M 29.45%	-21.68M 52.83%	-21.24M 2.05%	-29.49M 38.85%
income tax expense	-2 -			674K -	46K 93.18%	-537K 1,267.39%	53K 109.87%	43K 18.87%	32K 25.58%
net income	-12.50M -	-15.14M 21.13%		-14.58M -	-18.66M 27.99%	-13.44M 27.96%	-20.11M 49.60%	-14.19M 29.45%	-21.68M 52.83%	-21.24M 2.05%	-29.49M 38.85%
weighted average shs out	26.65M -	24.67M 7.42%	25.17M 2.03%		25.17M -	24.67M 1.99%	25.17M 2.03%		27.98M -	33.00M 17.95%	33.06M 0.19%
weighted average shs out dil	26.65M -	24.67M 7.42%	25.17M 2.03%		25.17M -	24.67M 1.99%	25.17M 2.03%		27.98M -	33.00M 17.95%	33.06M 0.19%
eps	-0.47 -	-0.61 29.79%	-0.68 11.48%	0 100%	-0.74 Infinity%	-0.54 27.03%	-0.80 48.15%	0 100%	-0.77 Infinity%	-0.64 16.88%	-0.89 39.06%
epsdiluted	-0.47 -	-0.61 29.79%	-0.68 11.48%	0 100%	-0.74 Infinity%	-0.54 27.03%	-0.80 48.15%	0 100%	-0.77 Infinity%	-0.64 16.88%	-0.89 39.06%

LXEO

COM:LEXEOTX

Lexeo

Last Close

6.12

21/11 21:00

Market Cap

541.62M

Beta: -

Volume Today

155.88K

Avg: -

Preview